Thalidomide, an antiangiogenic agent with clinical activity in cancer

被引：21
|
作者：
Ng, SSW [1 ]
Brown, M [1 ]
Figg, WD [1 ]
机构：
[1] Natl Canc Inst, Mol Pharmacol Sect, Canc Therapeut Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
来源：
BIOMEDICINE & PHARMACOTHERAPY | 2002年 / 56卷 / 04期
关键词：
thalidomide; HIV-infection; bFGF; VEGF;
D O I：
10.1016/S0753-3322(02)00177-4
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Despite the teratogenic past of thalidomide, there is recent evidence indicating the drug's efficacy in the management of various diseases from immune disorders to cancers. The history, pharmacodynamic and pharmacokinetic properties of thalidomide in the clinic are discussed in this review article. (C) 2002 Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码：194 / 199
页数：6
相关论文
共 50 条
  • [1] In vitro antiangiogenic activity of thalidomide analogues
    Ng, SSW
    Kruger, EA
    Luzzio, FA
    Eger, K
    Guetschow, M
    Hauschildt, S
    Hecker, T
    Teubert, U
    Weiss, M
    Figg, WD
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S82 - S82
  • [2] On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma
    Ribatti, A
    Vacca, A
    ANNALS OF HEMATOLOGY, 2003, 82 (04) : 262 - 262
  • [3] On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma
    D. Ribatti
    A. Vacca
    Annals of Hematology, 2003, 82 : 262 - 262
  • [4] Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study
    PP Piccaluga
    G Visani
    SA Pileri
    S Ascani
    T Grafone
    A Isidori
    M Malagola
    C Finelli
    G Martinelli
    P Ricci
    M Baccarani
    S Tura
    Leukemia, 2002, 16 : 1609 - 1614
  • [5] Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study
    Piccaluga, PP
    Visani, G
    Pileri, SA
    Ascani, S
    Grafone, T
    Isidori, A
    Malagola, M
    Finelli, C
    Martinelli, G
    Ricci, P
    Baccarani, M
    Tura, S
    LEUKEMIA, 2002, 16 (09) : 1609 - 1614
  • [6] Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues
    Ng, SSW
    Gütschow, M
    Weiss, M
    Hauschildt, S
    Teubert, U
    Hecker, TK
    Luzzio, FA
    Kruger, EA
    Eger, K
    Figg, WD
    CANCER RESEARCH, 2003, 63 (12) : 3189 - 3194
  • [7] Thalidomide as an anti-cancer agent
    Kumar, S
    Witzig, TE
    Rajkumar, SV
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2002, 6 (02) : 160 - 174
  • [8] Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs
    Peach, Megan L.
    Beedie, Shaunna L.
    Chau, Cindy H.
    Collins, Matthew K.
    Markolovic, Suzana
    Luo, Weiming
    Tweedie, David
    Steinebach, Christian
    Greig, Nigel H.
    Guotschow, Michael
    Vargesson, Neil
    Nicklaus, Marc C.
    Figg, William D.
    MOLECULES, 2020, 25 (23):
  • [9] Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogs.
    Luzzio, FA
    Ng, SSW
    Gutschow, M
    Hauschildt, S
    Weiss, M
    Teubert, U
    Kruger, E
    Mayorov, AV
    Eger, K
    Figg, WD
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U197 - U197
  • [10] Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts
    Kinuya, S
    Kawashima, A
    Yokoyama, K
    Koshida, K
    Konishi, S
    Watanabe, N
    Shuke, N
    Bunko, H
    Michigishi, T
    Tonami, N
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (08) : 1084 - 1089
12345